NO20091169L - Matriks metalloproteinasehemmere - Google Patents

Matriks metalloproteinasehemmere

Info

Publication number: NO20091169L
Authority: NO; Norway
Prior art keywords: compounds; present; matrix metalloproteinase; treatment; diseases
Prior art date: 2006-08-22

Application number

NO20091169A

Other languages

English (en)

Norwegian (no)

Inventor

Venkata P Palle

Manoj Kumar Khera

Sunanda G Dastidar

Viswajanani J Sattigeri

Ranadheer Reddy

Manoj Kumar Tiwari

Ajay Soni

Abdul Rehman Abdul Rauf

Sony Joseph

Arpita Musib

Punit Kumar Srivastava

Original Assignee

Ranbaxy Lab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-22

Filing date

2009-03-19

Publication date

2009-05-18

2009-03-19 Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd

2009-05-18 Publication of NO20091169L publication Critical patent/NO20091169L/no

Links

239000003771 matrix metalloproteinase inhibitor Substances 0.000 title abstract 2
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 4
208000027866 inflammatory disease Diseases 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
208000019693 Lung disease Diseases 0.000 abstract 1
102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
206010027476 Metastases Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
-1 amino substituted carboxylic acids Chemical class 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
208000007565 gingivitis Diseases 0.000 abstract 1
230000000302 ischemic effect Effects 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
230000009401 metastasis Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
230000002018 overexpression Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
206010039083 rhinitis Diseases 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Indole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)

NO20091169A 2006-08-22 2009-03-19 Matriks metalloproteinasehemmere NO20091169L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN1880DE2006		2006-08-22
PCT/IB2007/053340 WO2008023336A2 (en)	2006-08-22	2007-08-21	Matrix metalloproteinase inhibitors

Publications (1)

Publication Number	Publication Date
NO20091169L true NO20091169L (no)	2009-05-18

Family

ID=38961876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091169A NO20091169L (no)	2006-08-22	2009-03-19	Matriks metalloproteinasehemmere

Country Status (40)

Country	Link
US (3)	US8507670B2 (de)
EP (3)	EP2322507A1 (de)
JP (2)	JP5399902B2 (de)
KR (1)	KR101467590B1 (de)
CN (1)	CN101528691B (de)
AP (1)	AP2690A (de)
AR (1)	AR063945A1 (de)
BR (1)	BRPI0715231A2 (de)
CA (1)	CA2661299A1 (de)
CL (1)	CL2007002427A1 (de)
CO (1)	CO6150172A2 (de)
CR (2)	CR10674A (de)
CU (2)	CU23830B1 (de)
CY (1)	CY1113444T1 (de)
DK (1)	DK2074093T3 (de)
EA (1)	EA016567B1 (de)
ES (1)	ES2397284T3 (de)
GE (1)	GEP20125458B (de)
HR (1)	HRP20121079T1 (de)
IL (2)	IL197097A0 (de)
JO (1)	JO2868B1 (de)
MA (1)	MA30674B1 (de)
ME (1)	ME00594B (de)
MX (1)	MX2009001963A (de)
MY (1)	MY155277A (de)
NI (1)	NI200900028A (de)
NO (1)	NO20091169L (de)
NZ (1)	NZ574905A (de)
PH (1)	PH12012502420A1 (de)
PL (1)	PL2074093T3 (de)
PT (1)	PT2074093E (de)
RS (1)	RS52575B (de)
SG (1)	SG174089A1 (de)
SI (1)	SI2074093T1 (de)
SM (1)	SMP200900018B (de)
TN (1)	TN2009000054A1 (de)
TW (2)	TW201336829A (de)
UA (1)	UA95115C2 (de)
WO (1)	WO2008023336A2 (de)
ZA (1)	ZA200901427B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0321538D0 (en) *	2003-09-13	2003-10-15	Glaxo Group Ltd	Therapeutically useful compounds
BRPI0715231A2 (pt) *	2006-08-22	2013-06-25	Ranbaxy Lab Ltd	compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto
KR20130042590A (ko)	2010-07-30	2013-04-26	랜박시 래보러터리스 리미티드	기질 메탈로프로테나제 저해제
AU2012253653A1 (en)	2011-05-10	2013-05-02	Gilead Sciences, Inc.	Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (de)	2011-07-01	2018-04-28
TWI622583B (zh)	2011-07-01	2018-05-01	基利科學股份有限公司	作為離子通道調節劑之稠合雜環化合物
CN103751797B (zh) *	2013-12-30	2015-08-19	浙江工业大学	一种具有双重疗效的酶触释药制剂、其制备方法及应用
CN115925679A (zh) *	2014-12-24	2023-04-07	株式会社Lg化学	作为gpr120激动剂的联芳基衍生物
CN110339205B (zh) *	2019-08-19	2021-08-24	山东德信生物科技有限公司	富氢水组合物在抑制六价铬诱导的df-1细胞内质网应激及自噬中的应用
CN110437311B (zh) *	2019-08-27	2022-05-20	南京安吉生物科技有限公司	一种多肽及其应用
WO2021092163A1 (en) *	2019-11-06	2021-05-14	Nocion Therapeutics, Inc.	Phosphonium ion channel blockers and methods for use
US11673884B2 (en)	2019-11-14	2023-06-13	Foresee Pharmaceuticals Co., Inc.	Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
US20240288450A1 (en) *	2021-06-16	2024-08-29	Arizona Board of Regents on Behalf of the Univerity of Arizona	Systems and methods for monitoring and treating stroke

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1113690B (de)	1957-02-27	1961-09-14	Merck & Co Inc	Verfahren zur Herstellung von in 11-Stellung durch sauerstoffhaltige Gruppen substituierten 16-Methyl-1, 4-pregnadien-17ª‡-ol-3, 20-dion-Verbindungen
GB869511A (en)	1958-05-26	1961-05-31	Upjohn Co	Improvements in or relating to steroids and the manufacture thereof
US3007923A (en)	1959-01-22	1961-11-07	Lab Francais Chimiotherapie	Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
GB1200886A (en)	1966-09-23	1970-08-05	Allen & Hanburys Ltd	Phenylaminoethanol derivatives
US3937838A (en)	1966-10-19	1976-02-10	Aktiebolaget Draco	Orally active bronchospasmolytic compounds and their preparation
US3700681A (en)	1971-02-16	1972-10-24	Pfizer	2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines
DE2305092A1 (de)	1972-02-05	1973-08-16	Yamanouchi Pharma Co Ltd	Alpha-aminomethylbenzylalkoholderivate
US3994974A (en) *	1972-02-05	1976-11-30	Yamanouchi Pharmaceutical Co., Ltd.	α-Aminomethylbenzyl alcohol derivatives
SE378109B (de) *	1972-05-19	1975-08-18	Bofors Ab
US4011258A (en)	1973-06-21	1977-03-08	Aktiebolaget Draco	Orally active bronchospasmolytic compounds
CY1273A (en)	1980-07-09	1985-03-08	Draco Ab	1-(dihydroxyphenyl)-2-amino-ethanol derivatives;preparation,compositions and intermediates
ZW6584A1 (en) *	1983-04-18	1985-04-17	Glaxo Group Ltd	Phenethanolamine derivatives
CA1240708A (en) *	1983-11-15	1988-08-16	Johannes K. Minderhoud	Process for the preparation of hydrocarbons
DE122010000024I1 (de) *	1990-02-19	2010-07-08	Novartis Ag	Acylverbindungen
GR1001529B (el) *	1990-09-07	1994-03-31	Elmuquimica Farm Sl	Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5789434A (en)	1994-11-15	1998-08-04	Bayer Corporation	Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
ATE206416T1 (de) *	1995-06-02	2001-10-15	Warner Lambert Co	Trizyklische verbindungen als matrix- metalloproteinase inhibitoren
JP2002514179A (ja) *	1996-09-04	2002-05-14	ワーナー―ランバート・コンパニー	マトリックスメタロプロテイナーゼの阻害剤としてのビフェニル酪酸およびその誘導体
MY117687A (en) *	1996-10-31	2004-07-31	Bayer Corp	Substituted 4-biphenyl-4-hydroxybutric acid derivatives as matrix metalloprotease inhibitors
FR2780402B1 (fr) *	1998-06-30	2001-04-27	Adir	Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU4229499A (en) *	1998-07-30	2000-02-21	Warner-Lambert Company	Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
HU222773B1 (hu) *	2000-04-21	2003-10-28	Richter Gedeon Vegyészeti Gyár Rt.	Eljárás egy ismert tetrazolszármazék előállítására
GB0111523D0 (en) *	2001-05-11	2001-07-04	Glaxo Group Ltd	Chemical compounds
GB0312654D0 (en) *	2003-06-03	2003-07-09	Glaxo Group Ltd	Therapeutically useful compounds
GB0314488D0 (en)	2003-06-20	2003-07-23	Glaxo Group Ltd	Therapeutically useful compounds
GB0321538D0 (en) *	2003-09-13	2003-10-15	Glaxo Group Ltd	Therapeutically useful compounds
KR101274309B1 (ko) *	2005-02-22	2013-06-13	랜박시 래보러터리스 리미티드	천식 및 기타 질병의 치료를 위한 기질 메탈로프로테나제저해제로서 5-페닐-펜탄산 유도체
BRPI0715231A2 (pt) *	2006-08-22	2013-06-25	Ranbaxy Lab Ltd	compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto

2007
- 2007-08-21 BR BRPI0715231-0A2A patent/BRPI0715231A2/pt not_active IP Right Cessation
- 2007-08-21 ME MEP-2009-59A patent/ME00594B/me unknown
- 2007-08-21 DK DK07826082.5T patent/DK2074093T3/da active
- 2007-08-21 MY MYPI20090639A patent/MY155277A/en unknown
- 2007-08-21 AP AP2009004784A patent/AP2690A/xx active
- 2007-08-21 MX MX2009001963A patent/MX2009001963A/es active IP Right Grant
- 2007-08-21 EP EP10196009.4A patent/EP2322507A1/de not_active Withdrawn
- 2007-08-21 JO JO2007338A patent/JO2868B1/en active
- 2007-08-21 SG SG2011060019A patent/SG174089A1/en unknown
- 2007-08-21 GE GEAP200711178A patent/GEP20125458B/en unknown
- 2007-08-21 EP EP12163184.0A patent/EP2474531A3/de not_active Withdrawn
- 2007-08-21 EP EP07826082A patent/EP2074093B1/de active Active
- 2007-08-21 WO PCT/IB2007/053340 patent/WO2008023336A2/en not_active Ceased
- 2007-08-21 KR KR1020097005737A patent/KR101467590B1/ko not_active Expired - Fee Related
- 2007-08-21 CA CA002661299A patent/CA2661299A1/en not_active Abandoned
- 2007-08-21 CN CN200780038726.2A patent/CN101528691B/zh not_active Expired - Fee Related
- 2007-08-21 PL PL07826082T patent/PL2074093T3/pl unknown
- 2007-08-21 HR HRP20121079TT patent/HRP20121079T1/hr unknown
- 2007-08-21 EA EA200970214A patent/EA016567B1/ru not_active IP Right Cessation
- 2007-08-21 PT PT78260825T patent/PT2074093E/pt unknown
- 2007-08-21 CL CL200702427A patent/CL2007002427A1/es unknown
- 2007-08-21 SI SI200731061T patent/SI2074093T1/sl unknown
- 2007-08-21 ES ES07826082T patent/ES2397284T3/es active Active
- 2007-08-21 UA UAA200902501A patent/UA95115C2/ru unknown
- 2007-08-21 NZ NZ574905A patent/NZ574905A/en not_active IP Right Cessation
- 2007-08-21 JP JP2009525162A patent/JP5399902B2/ja not_active Expired - Fee Related
- 2007-08-21 RS RS20120558A patent/RS52575B/sr unknown
- 2007-08-21 US US12/438,182 patent/US8507670B2/en not_active Expired - Fee Related
- 2007-08-22 TW TW102120084A patent/TW201336829A/zh unknown
- 2007-08-22 TW TW096131028A patent/TW200817345A/zh unknown
- 2007-08-22 AR ARP070103738A patent/AR063945A1/es unknown
2009
- 2009-02-17 IL IL197097A patent/IL197097A0/en unknown
- 2009-02-20 TN TN2009000054A patent/TN2009000054A1/fr unknown
- 2009-02-20 CU CU2009000025A patent/CU23830B1/es active IP Right Grant
- 2009-02-23 CO CO09017757A patent/CO6150172A2/es unknown
- 2009-02-27 ZA ZA200901427A patent/ZA200901427B/xx unknown
- 2009-02-27 MA MA31675A patent/MA30674B1/fr unknown
- 2009-03-04 NI NI200900028A patent/NI200900028A/es unknown
- 2009-03-16 SM SM200900018T patent/SMP200900018B/it unknown
- 2009-03-19 NO NO20091169A patent/NO20091169L/no not_active Application Discontinuation
- 2009-03-20 CR CR10674A patent/CR10674A/es unknown
2011
- 2011-06-15 CU CU20110134A patent/CU20110134A7/es unknown
2012
- 2012-06-13 IL IL220353A patent/IL220353A0/en unknown
- 2012-12-05 PH PH12012502420A patent/PH12012502420A1/en unknown
- 2012-12-10 CY CY20121101194T patent/CY1113444T1/el unknown
2013
- 2013-02-19 JP JP2013030107A patent/JP2013151500A/ja active Pending
- 2013-07-08 US US13/936,439 patent/US8846910B2/en not_active Expired - Fee Related
- 2013-07-08 US US13/936,382 patent/US8816073B2/en not_active Expired - Fee Related
2014
- 2014-09-08 CR CR20140412A patent/CR20140412A/es unknown

Also Published As

Publication number	Publication date
JP2013151500A (ja)	2013-08-08
SI2074093T1 (sl)	2012-12-31
JP5399902B2 (ja)	2014-01-29
CR20140412A (es)	2014-10-22
CA2661299A1 (en)	2008-02-28
CN101528691A (zh)	2009-09-09
PL2074093T3 (pl)	2013-03-29
CU20110134A7 (es)	2012-01-31
CR10674A (es)	2009-04-30
NZ574905A (en)	2011-12-22
RS52575B (sr)	2013-04-30
AP2009004784A0 (en)	2009-02-28
US8816073B2 (en)	2014-08-26
US20130302378A1 (en)	2013-11-14
PH12012502420A1 (en)	2015-10-12
SMAP200900018A (it)	2009-05-11
CU23830B1 (es)	2012-10-15
TW201336829A (zh)	2013-09-16
MEP5909A (en)	2011-12-20
ES2397284T3 (es)	2013-03-06
SG174089A1 (en)	2011-09-29
PT2074093E (pt)	2013-01-24
US8846910B2 (en)	2014-09-30
HK1135684A1 (en)	2010-06-11
EP2322507A1 (de)	2011-05-18
MX2009001963A (es)	2009-03-30
TW200817345A (en)	2008-04-16
ZA200901427B (en)	2010-03-31
CO6150172A2 (es)	2010-04-20
EP2474531A3 (de)	2013-12-04
MY155277A (en)	2015-09-30
EA016567B1 (ru)	2012-05-30
KR20090053922A (ko)	2009-05-28
CY1113444T1 (el)	2016-06-22
SMP200900018B (it)	2010-05-07
UA95115C2 (en)	2011-07-11
CU20090025A7 (es)	2011-07-11
AR063945A1 (es)	2009-03-04
CN101528691B (zh)	2014-11-26
CL2007002427A1 (es)	2008-03-14
NI200900028A (es)	2011-04-06
WO2008023336A2 (en)	2008-02-28
AU2007287230A1 (en)	2008-02-28
JO2868B1 (en)	2015-03-15
US20130295141A1 (en)	2013-11-07
GEP20125458B (en)	2012-03-26
IL220353A0 (en)	2012-07-31
WO2008023336A3 (en)	2008-04-24
DK2074093T3 (da)	2012-11-19
MA30674B1 (fr)	2009-08-03
BRPI0715231A2 (pt)	2013-06-25
EP2074093A2 (de)	2009-07-01
EP2074093B1 (de)	2012-10-10
AP2690A (en)	2013-07-15
US8507670B2 (en)	2013-08-13
KR101467590B1 (ko)	2014-12-01
US20100081610A1 (en)	2010-04-01
HRP20121079T1 (hr)	2013-01-31
EP2474531A2 (de)	2012-07-11
TN2009000054A1 (en)	2010-08-19
IL197097A0 (en)	2009-11-18
ME00594B (me)	2011-12-20
JP2010501545A (ja)	2010-01-21
EA200970214A1 (ru)	2009-06-30

Legal Events

Date	Code	Title	Description
2017-03-20	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
UA95115C2 (en)	2011-07-11	Matrix metalloproteinase inhibitors
PH12013500198A1 (en)	2013-03-11	Matrix metalloproteinase inhibitors
EA201390404A1 (ru)	2013-09-30	Ингибиторы матричной металлопротеиназы
EA201390405A1 (ru)	2014-05-30	Ингибиторы матричной металлопротеиназы
EA201291273A1 (ru)	2013-06-28	Ингибиторы киназ, регулирующих апоптозный сигнал
NO20082000L (no)	2008-06-09	Pyrimidinamidforbindelser som PGDS-inhibitorer
HRP20050375B1 (hr)	2014-03-14	Taljeni azol-pirimidin derivati
NO20083561L (no)	2008-10-16	Forbindelser for behandling av inflammatoriske forstyrrelser
EA201070328A1 (ru)	2010-08-30	Соединения триазолопиридина и их применение в качестве ингибиторов ask
MX2009009443A (es)	2009-09-14	Compuestos de pirimidina hidrazida como inhibidores de pgds.
CY1114804T1 (el)	2016-12-14	Νεες ενωσεις 951: ενα διφαινυλοξυπροπανοϊκο οξυ ως ρυθμιστης crth2 και ενδιαμεσες ενωσεις
ZA200803327B (en)	2009-09-30	Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
PA8799201A1 (es)	2009-05-15	Tigeciclina y metodos para preparar intermedios
NO20092528L (no)	2009-08-26	Krystallinske kaliumsalter av lipoksin A4-analoger
NO20080457L (no)	2008-01-29	Kjemiske forbindelser
AR079441A1 (es)	2012-01-25	Derivados de heterociclos-piperidinas condensadas piperazinil-1-alcanona o de heterociclo-pirrolidinas condensadas-piperazinil-1-alcanona y su utiliza-cion como inhibidores de p75
WO2010042649A3 (en)	2010-11-18	PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
EA201291235A1 (ru)	2013-04-30	Новые способы
UA98292C2 (ru)	2012-05-10	Производные 5-фенилпентаноевой кислоты как ингибиторы матричной металлопротеиназы для лечения астмы и других заболеваний
EA200701348A1 (ru)	2007-12-28	Сульфониламиноциклические соединения и их применение
ATE320433T1 (de)	2006-04-15	2-thia-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
TW200640905A (en)	2006-12-01	Monopotassium salt of an IκB kinase inhibitor
ATE516279T1 (de)	2011-07-15	N-hydroxyamidderivate und ihre verwendung
NO20061290L (no)	2006-05-22	Nye forbindelser
UA94915C2 (ru)	2011-06-25	Производные бифенилоксиуксусной кислоты, промежуточные соединения и способ лечения болезни, опосредствованной простагландинами (варианты)